RNAZ ▼ -5.9% - TransCode Therapeutics, Inc.
$RNAZ RNAZ - TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
28-SEP-2026 08:04 AM ET
Share this post
More filings for $RNAZ
RNAZ ▲ +6.8% - TransCode Therapeutics, Inc.Sep 22, 2026RNAZ ▼ -7.3% - TransCode Therapeutics, Inc.Sep 10, 2026RNAZ ▲ +16.6% - TransCode Therapeutics, Inc.Aug 31, 2026$RNAZ SEC Filing Update (03-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 3, 2026$RNAZ SEC Filing Update (28-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 28, 2026$RNAZ SEC Filing Update (28-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 28, 2026
View full $RNAZ filing history →💬 Comments
Loading comments…
Leave a comment